Scarica l'app Stockscreener
4.87
2.84%
0.14
Precedente Chiudi:
$4.73
Aprire:
$4.77
Volume 24 ore:
43,252
Relative Volume:
0.14
Capitalizzazione di mercato:
$389.73M
Reddito:
$351.37M
Utile/perdita netta:
$-169.52M
Rapporto P/E:
-2.2932
EPS:
-2.1237
Flusso di cassa netto:
$-147.86M
1 W Prestazione:
+1.87%
1M Prestazione:
+8.34%
6M Prestazione:
+19.52%
1 anno Prestazione:
+24.73%
Intervallo 1D:
$4.74
$4.924
Intervallo di 1 settimana:
$4.67
$4.924
Portata 52W:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 284-8891
Indirizzo
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.87 | 378.53M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
485.51 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
677.82 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
895.81 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.85 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
284.20 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus - European AIDS Treatment Group
Atea Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AVIR - TradingView
AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020 - TradingKey
Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy - TipRanks
Atea Pharmaceuticals (AVIR) Faces Modest Decline Near Key Support LevelIchimoku Kumo Twist - dars.gov.et
Atea Pharmaceuticals Starts Phase 1 AT-587 Trial - t.co
William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating - Moomoo
Atea begins phase 1 trial of hepatitis E treatment AT-587 - Investing.com UK
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
Hepatitis E Has No Approved Treatments as Atea Begins Human Trial - Stock Titan
AVIR Q1 2026 Earnings: Narrower-than-expected Loss Drives Modest Stock GainCost Structure Review - DonanımHaber
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) Proxy filing Summary - Quartr
Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary - Quartr
Atea Pharmaceuticals (AVIR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Atea Pharmaceuticals (AVIR) AGM 2026 Summary - Quartr
Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary - Quartr
Atea Pharmaceuticals Inc (AVIR:UW): Stock Price, Quote and News - BNN Bloomberg
AVIRAtea Pharmaceuticals Inc Short Interest - Finviz
Atea Pharmaceuticals Gains 2.67% as Stock Approaches Key Resistance LevelMoney Flow Index - dars.gov.et
Atea Pharmaceuticals (AVIR) Q1 2026 Earnings: Beat on EPS Despite Pre-Revenue Status; Stock Climbs 2.67%Consensus Forecast Report - dars.gov.et
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Enterprise value to EBIT forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to sales forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Atea Pharmaceuticals Inc (AVIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (NASDAQ:AVIR) Refocuses Antiviral Pipeline - Kalkine Media
Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR) - TradingView
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVIR Forecast — Price Target — Prediction for 2027 - TradingView
Atea completes enrollment in phase 3 hepatitis C trial By Investing.com - Investing.com Australia
Atea completes enrollment in phase 3 hepatitis C trial - Investing.com UK
Atea Pharmaceuticals Completes Patient Enrollment in Phase - GlobeNewswire
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - Sahm
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Nigeria
Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs - Stock Titan
[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Equity awards boost Atea (AVIR) director Barbara Duncan’s holdings - Stock Titan
Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR) - Stock Titan
Atea Pharmaceuticals (AVIR) director receives new options and RSU awards - Stock Titan
Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director - Stock Titan
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atea Pharmaceuticals Inc Azioni (AVIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
536,097 |
| DUNCAN BARBARA GAYLE | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Polsky Bruce | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
124,806 |
| Murphy Polly A. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
121,745 |
| Adams Jerome M. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Corcoran Andrea | See Remarks |
Mar 11 '26 |
Option Exercise |
1.24 |
60,000 |
74,400 |
823,576 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Feb 03 '26 |
Option Exercise |
1.24 |
300,000 |
372,000 |
767,830 |
0.58%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):